Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | JAK1 | P23458 | 3/20 | 0.41 |
| ▸ | JAK3 | P52333 | 3/20 | 0.41 |
| ▸ | EIF2AK4 | Q9P2K8 | 9/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | CCNK | O75909 | 2/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2040086 | 0.91 | ADORA2A (0.43) | JAK2JAK1JAK3EIF2AK4ADORA2A | |
| SCHEMBL2033578 | 0.90 | FLT3 (0.46) | JAK2JAK1JAK3FLT3 | |
| SCHEMBL2033576 | 0.90 | FLT3 (0.46) | JAK2JAK1JAK3FLT3 | |
| SCHEMBL15194229 | 0.89 | EIF2AK4 (0.44) | IRAK4JAK2JAK1JAK3EIF2AK4 | |
| SCHEMBL2034708 | 0.86 | FLT3 (0.47) | JAK2JAK1JAK3FLT3 | |
| SCHEMBL2036766 | 0.86 | JAK2 (0.42) | IRAK4JAK2JAK1JAK3ADORA2A | |
| SCHEMBL2033799 | 0.86 | FLT3 (0.44) | JAK2JAK1JAK3EIF2AK4ADORA2A | |
| SCHEMBL2033549 | 0.85 | EIF2AK4 (0.39) | JAK2JAK1JAK3EIF2AK4ADORA2A | |
| SCHEMBL2051500 | 0.85 | EIF2AK4 (0.42) | EIF2AK4 | |
| SCHEMBL2036077 | 0.85 | JAK2 (0.49) | IRAK4JAK2JAK1JAK3EIF2AK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | IRAK4 12/4885JAK2 2/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.